The Experimental Irradiator Core, which has been in existence since 1986, maintains and operates sources of ionizing radiation for use by Cancer Center members in their experimental studies. Services performed by the resource staff include training in the operation of the sources, advice to users on the design of experiments using radiation, scheduling use of the sources, operating the sources when necessary, dosimetry for new experimental setups, and maintenance and repair of the resources. When not in use by members, these facilities are also available to non-members on an increased-fee basis. The primary resources of the facility are six Cs-137 irradiators. Three Nordion Gammacell 40 irradiators are primarily used for whole body irradiation of rodents or irradiation of attached cultured cells at a constant dose rate: The Shepherd Mark I irradiator is used primarily to deliver radiation to animal tumors or other partialbody irradiations at dose rates comparable to those used in external beam radiotherapy. However, this irradiator can deliver radiation at a broad range of dose rates for a variety of purposes, such as irradiation of cell suspensions or irradiation to high doses to sterilize implant material. The Gammacell 1000 irradiator is used to irradiate suspension cultures at a constant dose rate. The low-dose-rate irradiator, built in-house with a Shepherd 81 source, is used primarily to irradiate cell cultures at dose rates comparable to those used in tumor therapy with radioactive implants, but can deliver radiation at any rate below 2 Gy/hr and has also been used in studies of carcinogenesis from prolonged exposure to low-dose-rate radiation. It is anticipated that in 2008 an in-house-built image-guided small animal radiation research platform (SARRP) will be available to the Core facility. The SARRP is designed to produce the same degree of dose delivery precision in animal models as is currently achievable in human patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-45
Application #
7726485
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
45
Fiscal Year
2007
Total Cost
$13,501
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications